Premium
Ancillary approaches to plasminogen activators
Author(s) -
Bavarsad Shahripour Reza,
Alexandrov Andrei V.
Publication year - 2012
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2012.06688.x
Subject(s) - medicine , tissue plasminogen activator , cerebral blood flow , intensive care medicine , clinical trial , stroke (engine) , fibrinolytic agent , plasminogen activator , combination therapy , pharmacotherapy , cardiology , mechanical engineering , engineering
Acute ischemic stroke develops from an interruption in focal cerebral blood flow. In many cases, it is caused by an acute thromboembolism. Although systemic fibrinolytic therapy for acute ischemic stroke has been a significant breakthrough in the management of this disease, additional agents and methods that could improve or restore cerebral flow are necessary. Similarly to findings in acute myocardial infarction, combination pharmacotherapy has the potential to improve current thrombolytic treatment in acute ischemic stroke. In recent years, research efforts were directed toward various combination therapy with pharmacological and nonpharmacological methods. Several trials tested tissue plasminogen activator (t‐PA) in combination with antiplateletes and anticoagulants. Combination of t‐PA with nonpharmacological agents included sonothrombolysis (amplifying the thrombolytic effect), laser (neuro‐recovery), hypothermia (cytoprotection and decreasing brain swelling), and blood flow augmentation (increasing residual flow and recruitment of collateral vessels). This paper will review ongoing clinical trials and safety of these promising combinatory treatments.